Aikido Pharma Inc.

Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dominari Holdings, Inc. engages in wealth management, investment banking, sales and trading, and asset management through its subsidiaries. It operates through the Dominari Financial and Legacy AIkido business segments. The Dominari Financial segment represents the company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido segment includes Aikido Labs, which manages the investments holdings of the legacy entity. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,250,000...

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

Change Healthcare Inc

IsoRay

Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. AIkido Pharma is engaged in the development of small-molecule anti-cancer therapeutics.

Why Change Healthcare, Isoray And Alkido Are Moving Today

Shares of AIKI stock are skyrocketing after Aikido Pharma announced a new patent agreement for the use of psilocybin for cancer treatments. The post Aikido Pharma News: Why AIKI Stock Is Soaring Today appeared first on InvestorPlace.

Aikido Pharma News: Why AIKI Stock Is Soaring Today

NEW YORK, Jan. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. The technology is covered by four patent...

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

NEW YORK, Dec. 9, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer. Pancreatic ductal...

AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- AIkido Pharma Inc. (the "Company" or "AIkido") (NASDAQ: AIKI) today announced the results from the virtual 2020 Annual Meeting of Stockholders (the "Meeting") held on November 17, 2020 (the "Meeting"). All proposals that were presented to the...

AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its preclinical work on its next-generation chemotherapeutic, DHA-dFdC, and the solid lipid nanoparticle (SLN) drug delivery system to treat pancreatic cancer,...

AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) today announced that its work with research partner, Cogia BioTech LTD (www.cogia.de), has delivered several key updates on efforts to accelerate the study of PDA (Pancreatic Ductal Adenocarcinoma) treatments. As...

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

NEW YORK, Sept. 11, 2020 /PRNewswire/ -- AIkido Pharma Inc.

AIkido Pharma Inc. Announces Participation at the H.C.

AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore

NEW YORK, Aug. 14, 2020 /PRNewswire/ -- AIkido Pharma Inc.

AIkido Pharma Inc. to Present at The LD 500 Virtual Conference

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- AIkido Pharma Inc.

Option for Treatment for Coronavirus Extended

NEW YORK, July 9, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic. As previously announced, on April 13, 2020, AIkido executed a Master License...

AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus

Shares of nano-cap biotech Aikido Pharma Inc (NASDAQ: AIKI), are ripping higher following an announcement concerning worldwide licensing of an antiviral platform.

Penny Stock Surges On In-Licensing Antiviral Drug Platform

Aikido Pharma Inc. (NASDAQ: AIKI) is not necessarily a household name, but on Tuesday its shares made waves.

Aikido Pharma Could Be the Next Big Name in the Coronavirus Fight

News for Aikido Pharma Inc. Stock (AIKI)